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INTRODUCTION
Post-operative radiation therapy (RT) (1) and post-operative chemoradiation (2)
have been used for esophageal cancer patients deemed high risk for recurrence
after esophagectomy.
Defining opitmal RT target volume after esophagectomy is difficult due to
significant changes in patient anatomy and function.
Some radiation oncologists advocated the inclusion of the anastomotic site within
the irradiation volume due to concerns for potential increased relapse risk, while
others did not subscribe to this practice due to concerns for increased treatment
related toxicity.
We have previously reported patient outcome benefit using extended volume RT
In management with high risk esophageal cancer patients underwent
esophagectomy (3).
We have performed a Phase I study to evaluate the safety of subscription to this
practice.
1. Folk et al, Surgery, 113:1993
2. Bedard et al, Cancer, 91;2001
3. Yu et al, Radiother & Oncol, 73;2004
METHODS
From 2001 to 2006, a prospective phase I study to evaluate extended volume RT
covering anastomotic site post-esophagectomy was performed.
Eligible patients had resected esophageal cancer with high risk features, ie,
pathological findings as T3 or T4 disease and/or regional nodal involvement, with
or without surgical margins involvement.
Patients with distant metastasis (M1) or previously received RT were excluded.
Adjuvant therapy consisted of chemotherapy followed by concurrent
chemoradiation. Chemotherapy consisted of 4 cycles of ECF (epirubicin 50 mg/m2
day 1 and q 21 days, and cisplatinum 60 mg/m2 day 1 and q 21 days) with
epirubicin omitted during the concurrent phase with RT.
External beam RT utilized conformal CT planning, with multi-fields arrangement
tailored to the pathological findings and encompassed the primary tumor bed and
anastomotic site.
The initial target volume defined by margins of 5 cm above and below the pre-
surgical gross tumor volume, as well as 2 cm margin to cover the mediastinal
lymph nodes medially and laterally with superior margin extended 2 cm above the
anastomotic site (3).
The boost fields were 2 cm margins around the target volume.
The total RT dose was 5040 cGy at 180 cGy per fraction (the initial target volume
of 3060 cGy/17 fractions followed by 1980 cGy/11 fractions), delivered concurrently
with the third cycle of chemotherapy.
Treatment – related toxicities were assessed using NCI-CTC grading.
Patient outcomes were disease free survival (DFS) and overall survival (OS),
calculated by Kaplan-Meier method.
RESULTS
Out of 15 accrued patients there were 10 males and 5 females, age ranging
from 48 to 80 years, with median age of 64 years. The TNM stages
included one T3N0, two T2N1, eleven T3N1, and one T4N1. The histo-
pathology included 5 adenocarcinoma and 10 squamous cell carcinoma.
Resection margins were clear in 10 patients (Table 1).
Follow-up ranged from 3.5 to 53.4 months with median of 19 months.
Table 2 showed chemotherapy delay in 20% and dose reduction in 13.3%
of the patients prior to RT was needed while with concurrent RT it was 20%
and 6.6%, respectively.
The reasons for chemotherapy delay and dose reduction were as follows:
for chemotherapy delay including physician and patient’s choice in cycle 1;
febrile neutropenia, diarrhea in cycle 2; neutropenia in cycle 3 with RT; and
neutropenia and patient’s choice in cycle 4 with RT. For chemotherapy
dose reduction there was no dose reduction in cycle 1; febrile neurtopenia,
diarrhea and physician’s choice in cycle 2. Febrile neutropenia, mucositis,
handfoot syndrome in cycle 3 with RT and patient’s choice in cycle 4 with
RT. There were no RT delayed and dose reduction in the patient cohort.
During the follow-up period, there were 2 patients with Grade 1 for cough,
one patient with Grade 1 for nausea and vomiting, one patient with Grade 2
nausea and vomiting, one patient with Grade 2 diarrhea and abdominal
cramps, 2 patients with taste alteration and 3 patients with poor appetite
and low energy level.
There was no patient experienced treatment related esophagitis or
pneumonitis of greater than Grade 2 during treatment and in the follow-up
assessments.
There was no chemoradiation treatment related mortality in the study
cohort.
Disease recurrence occurred in 38% and the median time to relapse was
24 months (Figure1).
There was no tumor recurrence at the anastomotic site.
The median OS was 21 months (Figure 2).
Table 1:   Patient Demographics
Table 2:   Chemotherapy Delay and Dose Reduction
Chemotherapy
Patient  
No. Cycle 1 Cycle 2 Cycle 3 + RT Cycle 4 + RT
Delay
Dose 
Reduction
Delay
Dose
Reduction
Delay
Dose
Reduction
Delay
Dose
Reduction
1 - - - - - - - -
2 - - - - + - + +
3 - - - - - - - -
4 - - - - + - + -
5 - - - - - + - -
6 + - - + - - - -
7 - - + - - + - -
8 - - - - - - - -
9 - - + + - - + -
10 - - + - + - - -
11 - - - - - + - -
12 - - - - - - - -
13 - - - - - - - -
14 - - - - - - - -
15 - - - - - - - -
% 6.6% 0% 20% 13.3% 20% 20% 20% 6.6%
Figure 1:  Disease  Free Survival
CONCLUSION
Extended volume RT covering the anastomotic site in high risk patients
post esophagectomy is feasible and safe.
Figure  2: Overall Survival
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Patient Demographic
Age Median
Range 
(48-80 years)
Sex
Male
Female
10
5
Pathological Stage
T3N0
T2N1
T3N1
T4N1
1
2
11
1
Tumor Pathology
Squamous
Adenocarcinoma
10
5
Margin Status
Clear
Close/positive
10
5
